5-Amino-1MQ
Also known as: 5-Amino-1-Methylquinolinium
Molecular Identifiers
Overview
Selective inhibitor of the enzyme NNMT (nicotinamide N-methyltransferase). Small molecule (not a peptide) that increases cellular NAD+ levels, promoting lipid metabolism and adiposity reduction.
Small molecule (not a peptide). Does not have an amino acid sequence.
Half-life
~12 hours (oral)
Administration Route
Oral (capsules)
Category
Metabolic & Fat Loss
Mechanism of Action
- Selective inhibition of NNMT
- Increase in cellular NAD+ levels
- Promotion of fatty acid oxidation
- Reduction of adipocyte differentiation
- Improvement of insulin sensitivity
Dosage Protocol
Data compiled from the literature. This does not constitute medical advice.
| Parameter | Value |
|---|---|
| Dose | 50 mg per capsule |
| Frequency | 1-2 times daily |
| Timing | Morning and/or evening |
| Duration | 4-12 weeks |
Reported Side Effects
Adverse effects described in the literature. Severity and frequency vary between individuals.
- Mild headache
- Nausea
- Gastrointestinal discomfort
Product Properties
| Purity | >98% |
| Appearance | White capsules |
| Source | Chemical synthesis |
Presentations & Preparation
Vials of 5-Amino-1MQ found in the research market:
Reconstitution
- Diluent: N/A (oral capsules)
- Volume: N/A
- Product supplied in ready-made capsules
- No reconstitution required
Storage
- Lyophilized: Room temperature (up to 2 years)
- Reconstituted: N/A (capsules)
- Store in a dry place
- Protect from light and moisture
Related Peptides
Adipotide
0.5-1 mg/kg per injection (subcutaneous) · Once daily
AICAR
50-150 mg per injection · 2-3 times per week
AOD 9604
300-600 mcg per injection · Once daily
Cagrilintide
1.2-4.5 mg per week (subcutaneous) · Once weekly
Dulaglutide
0.75-4.5 mg per week (subcutaneous) · Once weekly
Exenatide
5-10 mcg per injection (subcutaneous) · Twice daily (Byetta) or once weekly (Bydureon)